|
| | Astragaloside A Basic information |
| Product Name: | Astragaloside A | | Synonyms: | ASTRAGALOSIDE IV(P);astragaloside A;Astragaloside IV;Astragaloside IV ,98%;Astragaloside IV(A);Astragaloside A(Astragaloside IV);Astramembrannin i;beta-D-Glucopyranoside, (3beta,6alpha,16beta,24R)-20,24-epoxy-16,25-dihydroxy-3-(beta-D-xylopyranosyloxy)-9,19-cyclolanostan-6-yl | | CAS: | 83207-58-3 | | MF: | C41H68O14 | | MW: | 784.97 | | EINECS: | | | Product Categories: | Inhibitors;API;Plant extracts | | Mol File: | 83207-58-3.mol |  |
| | Astragaloside A Chemical Properties |
| Boiling point | 895.7±65.0 °C(Predicted) | | density | 1.39±0.1 g/cm3(Predicted) | | storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | DMF: 20 mg/ml; DMSO: 30 mg/ml; DMSO:PBS(pH7.2) (1:1): 0.5 mg/ml | | form | A crystalline solid | | pka | 12.91±0.70(Predicted) | | InChI | InChI=1/C41H68O14/c1-35(2)24(54-33-29(48)26(45)20(44)17-51-33)9-11-41-18-40(41)13-12-37(5)31(39(7)10-8-25(55-39)36(3,4)50)19(43)15-38(37,6)23(40)14-21(32(35)41)52-34-30(49)28(47)27(46)22(16-42)53-34/h19-34,42-50H,8-18H2,1-7H3/t19-,20+,21-,22+,23-,24?,25-,26-,27+,28-,29+,30+,31-,32-,33-,34+,37+,38-,39+,40-,41+/s3 | | InChIKey | QMNWISYXSJWHRY-APZLXCBQNA-N | | SMILES | [C@@]123CC[C@]4(C)[C@]([H])([C@@H](O)C[C@@]4(C)[C@]1([H])C[C@H](O[C@H]1[C@H](O)[C@H]([C@H](O)[C@@H](CO)O1)O)[C@@]1([H])C(C)(C)C(O[C@@H]4OC[C@@H](O)[C@H](O)[C@H]4O)CC[C@]21C3)[C@@]1(C)CC[C@@H](C(O)(C)C)O1 |&1:0,3,5,7,10,12,15,17,18,20,21,23,28,35,38,40,42,46,48,52,r| | | LogP | 0.628 (est) | | CAS DataBase Reference | 83207-58-3 |
| | Astragaloside A Usage And Synthesis |
| Uses | Astragalosides are bioactive saponins isolated from dried roots of plants of the genus Astragalus, which is used in traditional Chinese medicine. Astragaloside A, also known as astragaloside IV, is known to have diverse protective effects for the cardiovascular, immune, digestive, and nervous systems. More specifically, it protects cardiomyocytes from apoptosis resulting from ischemia/reperfusion and inhibits inflammation signaled through TNF-α. Furthermore, astragaloside A stimulates angiogenesis, promotes the differentiation of neural stem cells, and increases neuroregeneration. | | Definition | ChEBI: A pentacyclic triterpenoid that is cycloastragenol having beta-D-xylopyranosyl and beta-D-glucopyranosyl residues attached at positions O-3 and O-6 respectively. It is isolated from <ital Astragalus membranaceus var mongholicus. | | benefits | Astragaloside A (Astragaloside IV) is the primary pure saponin isolated from Astragalus membranaceus, which has been widely used for the treatment of cardiovascular diseases. It is the primary pure saponin isolated from Astragalus membranaceus, which has been widely used for the treatment of cardiovascular diseases. Astragaloside IV improves post-ischemic heart function and ameliorated reperfusion arrhythmias accompanied by a significant increase in myocardial antioxidative enzyme superoxide dismutase activity in rat hearts in vitro. While, Astragaloside IV's protective effect on heart function can be partially abrogated by the nitric oxide synthase inhibitor, Nomega-nitro-L-arginine methyl ester. | | Health effects | As the main active ingredient of the Chinese medicine Astragalus membranaceus, Astragaloside A has a good regulatory effect on the heart. It can protect against ischemic and hypoxic cardiomyocytes, protect the heart structure, and enhance heart function. | | Pharmaceutical Applications |
Astrageloside A has multiple pharmacologic effects, including anti-inflammatory, antifibrotic, antioxidative stress, anti-asthma, antidiabetes, immunoregulation, and cardioprotective effect via numerous signaling pathways. According to the existing studies and clinical practices, Astragaloside A possesses potential for broad application in many diseases.
|
| | Astragaloside A Preparation Products And Raw materials |
|
